Last updated: 13.02.2014

Address: Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany

Tel: + 49 30 726247-0


Company description

NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology. The company is concentrating its attention on inflammatory diseases and haematological conditions. NOXXON’s lead compound, NOX-E36 for treatment of kidney inflammation, is currently undergoing phase I clinical testing. A second Spiegelmer compound, NOX A12 for use in stem cell transplantation, is scheduled to enter phase I clinical testing later this year.NOXXON’s goal is the in-house development of our own Spiegelmer products through Phase II clinical trials. Complementing its own programs, NOXXON works on multiple drug discovery and development projects with its partners Eli Lilly, F. Hoffmann-La Roche, and Pfizer. The pursuit of licensing partnerships and collaborative Research & Development efforts is an integral part of our business strategy and plays an important role in the company’s growth and success. This strategy reflects our strengths in drug discovery and the vast potential of our unique technology platform.

Products and services


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here